Assembly Biosciences Files 8-K on Operations
Ticker: ASMB · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financial-condition, sec-filing
Related Tickers: ASMB
TL;DR
ASMB filed an 8-K for operational and financial updates. No major news yet.
AI Summary
Assembly Biosciences, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not appear to contain specific financial figures or significant events beyond routine reporting requirements.
Why It Matters
This filing indicates Assembly Biosciences is providing updates on its financial condition and operations to the SEC. Investors should review the details within the filing for any material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on operations and financial condition without disclosing any new material events or significant financial changes.
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- March 28, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by Assembly Biosciences, Inc.?
The primary purpose of this 8-K filing is to report on the Registrant's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K filing reported?
This 8-K filing was reported on March 28, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at Two Tower Place, 7th Floor, South San Francisco, California 94080.
What is the Registrant's telephone number?
The Registrant's telephone number is (833) 509-4583.
What is the Standard Industrial Classification (SIC) code for Assembly Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Assembly Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-28 16:10:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
Filing Documents
- asmb-20240328.htm (8-K) — 43KB
- asmb-ex99_1.htm (EX-99.1) — 162KB
- 0000950170-24-038044.txt ( ) — 334KB
- asmb-20240328.xsd (EX-101.SCH) — 30KB
- asmb-20240328_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 28, 2024, Assembly Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release dated March 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: March 28, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2